Mar 26, 2024
Revised Interpretation of Sweat Chloride Test
Asthma
Omalizumab (Anti-IgE)
Bronchial thermoplasty
IL5 Drugs
IL4/1L13 blockers
Definition of Severe Asthma
COPD
Indications of LTOT (Long Term Oxygen Therapy) in COPD
Vaccination For COPD pts
EBUS-TBNA: Endobronchial Ultrasound Guided Transbronchial Needle Aspiration (of the lymph node) has a 90% sensitivity for identifying epithelial cancer and a 70% sensitivity for lymphoma (which is more likely to detect a recurrence of lymphoma than a leukemia from scratch). The EBUS-TBNA has an 80% increased sensitivity for sarcoidosis when paired with endobronchial biopsy.
ROSE: TBNA Biopsies: Rapid Onsite Cytological Examination Noble Gas MRI: Hyperpolarized 3He is the agent employed. It is used to evaluate airway ventilation and perfusion.
Further information regarding CT: Pulmonary arterial pressure is directly correlated with the quality of the central pulmonary arterial trunk near its first bifurcation. The s/o ↑ pulmonary artery pressure is measured at > 3 cms. There is a correlation between disease severity and the ratio of PA diameter to adj. aorta diameter (PA/A).
Modifies the GINA 2021 guidelines slightly. PD20 (Provocative dose 20): a dosage of methacholine that reduces FEVI by 20%. Value less than 400 µg: indicates hyperreactivity of the airways. In untreated patients, FeNo >35–40 ppb is suggestive of eosinophilic inflammation.
For patients with severe asthma on moderate to high close ICS, >20–25 ppb indicates noncompliance.
For patients whose asthma symptoms are not controlled by moderate to high doses of ICS and who have an IgE level of ≥ 30 IU/ml and a positive skin test or RAST to a perennial allergen. Individuals with FeNo > 20 ppb and an Eosinophil Count ≥ 260/l are the best responders.
Not recommended other than in the setting of a clinical trial
Recommended in patients with symptomatic on moderate to high dose ICS/LABA. With ≥2 exacerbations requiring oral steroid/year-Eosinophil count >= 300/µL. Agents-Anti-IL5-Mepolizumab, Reslizumab. Anti IL5R
-Benralizumab
Dupilumab. Same indications as IL5 drugs but can also be used in patients with eosinophil count <300/μl.
Uncontrolled asthma on step 5 medication or asthma requiring step 5 medication for control following co-morbidity evaluation, education, and trigger minimization.
The management recommendations in GOLD 2021 are mostly followed by HPIM 21st ed. Preserved Ratio Impaired Spirometry (PRISm COPD)
Patients in the COPD subgroup with FEV1 ≤ 80% but FEV and/or FVC > 70% . Emphysema usually strikes these people later in life, and they may advance straight to GOLD stages 3 or 4.
Individuals having a resting SpO2 of at least 88% or 89%. With erythrocytosis, right heart failure, pulmonary hypertension, or recently added advice
Lung Transplantation
Contraindications to Lung Transplantation | ||
Absolute Contraindications | Relative Contraindications | |
Surgical considerations | Anatomic abnormalities not amenable to transplant procedure | |
Age | >65 years | |
Functional status | Immobility, inability to participate in physical therapy/rehabilitation | Limited functional status as defined by 6-minute walk distance |
Medical comorbidities | Untreatable, irreversible organ dysfunction | Chronic kidney disease |
Active malignancy or malignancy with insufficient remission period | ||
Active bacterial bloodstream infection | Infection resistant to treatment or of high risk for posttransplant morbidity/mortality (Burkholderia cenocepacia, Mycobacterium abscesses) | |
Uncontrolled viral infection (HIV, hepatitis) | ||
Nutritional | BMI <18 or >30-35 | |
Psychosocial | Untreatable, irreversible psychiatric disorder with potential to impact transplant outcome | |
Active substance abuse | Limited social supports | |
Other circumstances that would complete ability to participate in and comply with posttransplant care | History of noncompliance with medical treatment |
Characteristics of the Ideal Lung Donor | |
Donor age | <55 years |
ABO compatibility | Identical |
Chest radiography | Clear |
PaO2:FiO2 | >300 on PEEP 5-cm H2O |
Tobacco History | <20 pack-years |
Chest Trauma | Absent |
Evidence of aspiration | Absent |
Prior thoracic surgery | None |
Sputum gram stain | Negative |
Bronchoscopy Findings | No purulent secretions |
Predictors of Survival After Lung Transplantation | ||
1 Year Survival | ≥10 Year Survival | |
Donor factors | HCV donor | |
Recipient factors | Age <70 years Diagnosis other than pulmonary fibrosis, pulmonary hypertension, sarcoidosis, A1AT O2 requirement <5LCl >2Outpatient at time of transplant Preserved recipient eGFR Total bilirubin <2 | Age 18-35 years |
Donor/Recipient Factors | Non female to male transplant Donor/recipient weight ratio >0.7 | Higher levels of HLA matching |
Operative factors | Avoidance of unplanned conversion to cardiopulmonary bypass Decreased ischemic time | Bilateral lung transplant |
Posttransplant factors | Pa07/Fi02>260 at 72h Absent need for postoperative ECMO support | Fewer hospitalizations for rejection |
Other factors | Higher center volume | Higher center volume |
Also Read: Special Considerations in Diabetes Mellitus
Hope you found this blog helpful for your NEET SS Pulmonology Preparation. For more informative and interesting posts like these, keep reading PrepLadder’s blogs.
Get access to all the essential resources required to ace your medical exam Preparation. Stay updated with the latest news and developments in the medical exam, improve your Medical Exam preparation, and turn your dreams into a reality!
Avail 24-Hr Free Trial